Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors

Area of Science:

• Oncology
• Hematology
• Molecular Biology

Background:

• Chronic myeloid leukemia (CML) is often treated with tyrosine kinase inhibitors (TKIs).
• BCR-ABL1 oncoprotein activity is key in CML pathogenesis.
• TKI resistance is a significant clinical challenge in CML management.

Purpose of the Study:

• To review molecular mechanisms of TKI resistance in CML.
• To highlight drug resistance conferring a survival advantage.
• To discuss novel strategies for overcoming TKI resistance.

Main Methods:

• Literature review of molecular mechanisms and clinical findings.
• Analysis of TKI resistance pathways in CML.
• Synthesis of recent advances in CML therapy.

Main Results:

• Point mutations in the ABL1 kinase domain are a primary cause of TKI resistance.
• 20-40% of TKI resistance cases are not explained by known mutations.
• Activation of alternative survival pathways contributes to resistance.
• Novel therapeutic strategies are emerging to combat TKI resistance.

Conclusions:

• Understanding TKI resistance mechanisms is crucial for effective CML treatment.
• Targeting resistance pathways offers a promising approach to improve cure rates.
• Advances in therapy are expanding treatment options for resistant CML.